EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Therapeutic advances in pulmonary fibrosis

Ekrem Temizel iD, Alexandre Franco Amaral, Punchalee Kaenmuang iD, Niamh Logan, Nazia Chaudhuri

Therapeutic Advances in Respiratory Disease · 2026

DOI: 10.1177/17534666261489541 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Therapeutic Advances in Respiratory Disease, 2026. Verfasst von Ekrem Temizel und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pulmonology and Sleep Medicine, HOCH Health Ostschweiz, Kantonsspital St. Gallen, St. Gallen, Switzerland. Hauptthemen laut MEDLINE: Idiopathic Pulmonary Fibrosis, Antifibrotic Agents, Pulmonary Fibrosis. Die Arbeit nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pharmacological treatment of idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) is evolving from two established antifibrotic agents towards a broader pipeline of therapies. Current standard treatment with nintedanib and pirfenidone slows the decline in forced vital capacity, but does not halt disease progression, and long-term use may be limited by tolerability issues. This review summarises major profibrotic mechanisms relevant to drug development and discusses therapies in advanced or emerging clinical programmes, including the recently FDA-approved nerandomilast, positive results from the phase 3 trial of inhaled treprostinil, as well as promising mid-stage, pathway-directed agents targeting a broad range of profibrotic signalling pathways. We also discuss how negative or terminated programmes highlight recurring limitations related to efficacy, safety, trial duration, endpoint selection, and patient heterogeneity. Finally, we outline current shifts in trial design and outcome assessment, including increasing emphasis on patient-centred and composite endpoints alongside physiological measures, and discuss the rationale for add-on and combination approaches in future antifibrotic therapy for IPF and PPF.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Idiopathic Pulmonary FibrosisAntifibrotic AgentsPulmonary FibrosisHumansDisease ProgressionAnimalsPyridonesSignal TransductionDrug DevelopmentIndoles

Stichwörter der Autor:innen

antifibrotic agentsidiopathic pulmonary fibrosisinterstitial lung diseasespulmonary fibrosis

Substanzen

Antifibrotic AgentsPyridonespirfenidoneIndolesnintedanib

Autor:innen und Institutionen

  • Department of Pulmonology and Sleep Medicine, HOCH Health Ostschweiz, Kantonsspital St. Gallen, St. Gallen, Switzerland.
  • Pulmonary Division, Cardiopulmonary Department, Instituto do Coração (InCor), Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo (USP), São Paulo, SP, Brazil.
  • Respiratory and Respiratory Critical Care Unit, Division of Internal Medicine, Faculty of Medicine, Prince of Songkla University, Songkhla, Thailand.
  • Department of Respiratory Medicine, Mercy University Hospital, Cork, Ireland.
  • School of Medicine, University of Ulster Faculty of Life and Health Sciences, Londonderry, UK.
  • Altnagelvin Area Hospital, Western Health and Social Care Trust, Londonderry, UK.

ORCID-Profile: Ekrem Temizel, Punchalee Kaenmuang

Zitieren

APA

Temizel, E., Franco Amaral, A., Kaenmuang, P., Logan, N., & Chaudhuri, N. (2026). Therapeutic advances in pulmonary fibrosis. Therapeutic Advances in Respiratory Disease. https://doi.org/10.1177/17534666261489541

Vancouver

Temizel E, Franco Amaral A, Kaenmuang P, Logan N, Chaudhuri N. Therapeutic advances in pulmonary fibrosis. Therapeutic Advances in Respiratory Disease. 2026. doi:10.1177/17534666261489541

BibTeX
@article{Temizel2026,
  author = {Temizel, Ekrem and Franco Amaral, Alexandre and Kaenmuang, Punchalee and Logan, Niamh and Chaudhuri, Nazia},
  title = {Therapeutic advances in pulmonary fibrosis},
  journal = {Therapeutic Advances in Respiratory Disease},
  year = {2026},
  doi = {10.1177/17534666261489541}
}
Kostenlos starten →